FDA批准的原料药库列表,美国Selleck高特异性分子库/高通量筛选列表,赛导通生物科技现货供应

首页 >> 分子库/高通量筛选 >> FDA批准的原料药库

 

 

FDA批准的原料药库 (96孔板)产品目录号. L1300

粉末:

剂量 价格

1mg/well ¥ 42903

2mg/well ¥ 58023

预溶在DMSO中:

剂量 价格

100μL/well (10mM solution) ¥ 22113

250μL/well (10mM solution) ¥ 44793

Customize Your Library

Contact Us

描述&优势

381种FDA批准的原料药的独特集合,可用于高通量筛选和高内涵筛选 。

帮助已有药物定位新的靶点。

通过临床实验,生物活性和安全性得到验证。

全部得到FDA批准。

与肿瘤学,心脏病理学, 抗炎反应,免疫学,神经医学, 痛觉缺失等等都有关。

结构多样,药效显著,可渗透细胞。

具有充分详细的结构说明,IC50值,及客户反馈资料。

NMR和HPLC技术保证产品高纯度。

产品详细信息

配制: 381种FDA批准的原料药制成冻干粉或预溶在DMSO溶液中。

96-孔板: 是

储存: -80°C 长期储存

稳定性: 6个月

发货: 蓝冰物流

包装: 惰性气体

FDA批准的原料药库目录册

如果您需要下载FDA批准的原料药库目录册(.xlxs和.SDF),请通过 info@selleckchem.com联系我们

FDA批准的原料药库全部组成

 

 

下载产品目录册及宣传资料

 

使用我公司Selleck产品的论文

Anti-myeloma activity of a multi targeted kinase inhibitor,AT9283, via potent Aurora Kinase and STAT3 inhibition either alone or in combination with lenalidomide.

[Loredana Santo, Teru Hideshima et al. Clin Cancer Res. 2011 May;17:3259-3271]

Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway

[Giorgio Zauli, Rebecca Voltan et al. Clin Cancer Res. 2011;17:762-770]

Rotavirus Replication Requires a Functional Proteasome for Effective Assembly of Viroplasms

[R. Contin,F. Arnoldi et al. Journal of virology. 2011 Mar;85:2781-2792]

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

[V Serra, M Scaltriti et al. Oncogene. 2011;1]

Identification and Characterization of Persistent Intracellular Human Immunodeficiency Virus Type 1 Integrase Strand Transfer Inhibitor Activity

[Yasuhiro Koh, Hillel Haim et al. Antimicrobial agents and chemotherapy. 2011 Jan;55:42-49]

Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro

[Nadine Ce´cile Luise Zembruski,Gabriele Bu¨chel et al. Journal Antimicrob Chemother. 2011 January;11]

Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: Delineation of anti-leukemic mechanisms of action

[Elodie Lainey, Sylvain The´pot et al. Biochemical Pharmacology. 2011;1]

Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression

[Young-Sun Kim, Hyeon-Ok Jin et al. Biochemical Pharmacology. 2011 August;82:216-226 ]

 

Write a comment

Comments: 0



赛导通生物科技联系方式:


上海市黄浦区江西中路261号509室,

近南京东路外滩


电话 400-168-1698


传真 021 3326 0586


邮箱: info@selleck.cn 

 技术: tech@selleck.cn



Selleck癌症肿瘤研究周刊


Stu.la 司途拉生物
Stu.la 司途拉生物